

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Follitropin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Anixa Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Follitropin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Anixa Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Step Down FSH Approach and Late Follicular Phase in Progesterone Level
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 29, 2017
Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Follitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Fertility Laboratories Of Colorado
Deal Size : Inapplicable
Deal Type : Inapplicable
In Vitro Maturation of Human Eggs
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in clinical studies for the treatment of Infertility.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 06, 2015
Lead Product(s) : Follitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Fertility Laboratories Of Colorado
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 07, 2013
Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Follicle Stimulating Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 19, 2010
Lead Product(s) : Follitropin
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
